Barney King Email & Phone Number

Palo Alto, Ca, Us

Palo Alto, Ca, Us

San Diego, Ca, Us

Principal in firm specializing in strategic planning, business development, organizational development, and due diligence activities, principally for the pharmaceutical and biotechnology industries, on behalf of companies and venture capital and private equity firms. Activities for clients have ranged from general consulting to filling functional positions such as CEO (including raising capital), head of R&D, head of clinical development and regulatory affairs, and medical monitor. Multiple development plans have been prepared for clients incoroporating all aspects of development from pre-clinical activities through registration. Assignments have spanned a broad range of clinical indications, e.g., rheumatoid arthritis, metabolic diseases, oncology, cardiovascular diseases, dermatology, pulmonary disease, neurologic diseases, etc. and multiple technologies.Other services have included providing due diligence and strategic planning for companies, venture capital firms, and non-profit organizations.

San Diego, Ca, Us

Teach course in Regulatory Affairs Masters Degree programCourse is entitled, "Issues in Clinical Trials". Course covers background and history of clinical development, planning and managing activities associated with clinical product development, ethical basis and safety of clinical trials, clinical trial design, clinical operations, regulatory affairs, regulatory strategy, and future developments in clinical development

Notre Dame, In, Us

Contract clinical research and data management for clinical trials in India. Extensive experience in set-up and operations for clinical product development at Indian clinical trial sites

Us

Part of senior management team. Participated in all management activities, including interaction with Board of Directors. Responsible for clinical development, clinical operations, regulatory affairs, and chemistry, manufacturing, control (CMC). During tenure, filed IMPDs in Hungary and Holland (2). Also completed individual regulatory filings in Bosnia, Serbia, Ukraine, Georgia. Completed filings to 22 individual local ethical review committees and central (national) ethical review committees in 5 countries. Initiated, conducted, and completed multi-national clinical trial in rheumatoid arthritis. Filed IND in US (Endocrinology & Metabolism) and completed filings to central IRB in US. Planned, initiated, conducted, and completed multicenter clinical trial in dyslipidemia. Extensive interactions with multiple CROs in U.S. and Europe.

Start-up high technology company focused in area of clinical bioinformatics. Business model included deployment of software in physician practices, generation of very powerful and deep database of clinical data, application of very powerful artificial intelligence software to enable pharmaceutical companies to improve identificationof well-characterized patients for enrollment into clinical trials and, by linking clinical databases with databases in genomics, proteomics, high-throughput screening, pharmacogenomics, toxicology, etc., significantly improving the processes of drug discovery and development.Responsible for all aspects of company activity. Took company through first funding round (beyond seed investment), first pharmaceutical partnership, and deployment at first clinical sites.

Durham, North Carolina, Us

One of largest contract research organization (CRO) in the world. Responsible for managing more than 200 people in San Diego office representing all disciplines in business, e.g. sales, proposal development, statistics, programming, data management, clinical operations, report writing, regulatory affairs, QC, QA, human resources, project management, IS support. Also responsible for developing and operating separate business unit (with separate P&L), based in San Diego, focused on small pharma-ceutical, medical device, biotechnology and diagnostics companies. Member of corporate executive committee.During first year organized, directed and complete facilities move, increasing space by 50%. Increased headcount in San Diego office and in Emerging Companies business unit. Revenue for Emerging Group increased by 90% for year; projection for following fiscal year was an additional 60% increase. Margins increased more than revenues during this period.

Officer of the company. Active participant in all strategic and operational aspects of the company. Responsible for all research and development activities relating to biological sciences, including all aspects of in-house high-throughput screening program, combinatorial biology, in vivo pharmacology, analytical sciences, animal sciences, medical and regulatory affairs, and clinical trial management. Became President of ChromaXome at time of acquisition by Trega in August 1997. Supervised 50 scientists (10 Ph.D. and 9 M.S.). Also responsible for organizing external corporate presentations, identifying potential technologies for consideration of licensing, interacting with potential licensors, analyzing potential opportunities, presenting recommendations to senior staff and board of directors. Responsible for many direct corporate interactions for the purposes of potential partnering opportunities in Japan, Europe and United States.Active participant in preparation of S-1 and all materials for IPO and participated actively in road show Initiated and developed business discussions for partnerships and served on management committees: Ono Pharmaceuticals (potential value in excess of $25 million), Chugai Pharmaceuticals (value in excess of $3 million in cash plus significant technology access and transfer), and Northwest NeuroLogic (key receptors for screening program) With head of chemistry, very effectively integrated biological and chemical research and development groups, permitting rapid screening, interpretation of data and analoging of positive compounds

Little Rock, Arkansas, Us

Hired to run and develop the Research and Development and Clinical Affairs groups. Led (until transfer to Segenix unit) the Project Team for the Company's lead product, Dermagraft*. Was responsible for all research programs, including skin, cartilage, bone, liver, bone marrow, intestine, and blood vessel. Was responsible for all clinical trial activity, including interactions with contract research organizations. Was responsible for all operations in the Clinical Production Laboratory, the manufacturing facility producing clinical trial supplies. Ultimately responsible for (at peak) a department of 60 individuals (company size: 110). Participated in all Senior Management functions of the company, including strategic planning and budgeting.Responsible for all aspects of planning, formation, leadership and operation of Segenix, a company spun off from parent for the purposes of commercialization of research products in areas of liver and bone marrow tissue engineering, bioreactors, and gene therapy. Activities also included fund raising and development of corporate alliances. Supervised 13 individuals (7 Ph.D.'s).

London, England, Gb

Initially Medical Director, North America, then promoted to Vice President, Worldwide.Initially directed a department of 28 individuals, including nurses, Ph.D.s, secretarial, data processing and clerical personnel. Provided direct medical support for all clinical trials and supervised clinical plan development, protocol development, case report form generation, trial monitoring, analysis of data, writing of reports for all clinical trials conducted in North America. Participated in Company Level Management and Product Development Committees.As VP, consolidated all medical and regulatory resources worldwide and incorporated a data management group into a single organization and then built the organization in order to support product development, registrational activities, and sales and marketing of approved products in all markets into which ConvaTec sold (68 countries worldwide). During this period, ConvaTec sales grew from $300 million per year to $450 million annually. Was responsible for all medical activities for ConvaTec worldwide, including development of Clinical Trial programs, management of trials, and data analysis for all ConvaTec products. Was responsible for all regulatory activities for ConvaTec worldwide, including preparation of dossiers for submission to regulatory authorities and interactions with regulatory agencies.Functioned as a member of ConvaTec Management Committee, ConvaTec Product Development Committee, Patent Committee and Diversification Committee. Interacted on a regular basis with Marketing, Business Development, Research and Development, Technical Operations and Regional and Local Business units.During this period, obtained MBA from Wharton.

Brentford, Middlesex, Gb

Served as Medical Monitor and Project Team Leader for compound (fenoldopam, dopamine-1 agonist for congestive heart failure, severe, hypertension, and chronic renal failure) with highest priority for development at SmithKline at time. Participated in Program Development for Carvedilol (Coreg). Responsible for filing NDA and IND. Consulted on other projects in infectious diseases, pulmonary, CNS, and cardiovascular diseases.As medical monitor responsible for protocol development, data review, AE monitoring, report writing, and FDA interactions.As Chairman, Worldwide Clinical Subcommittee supervised protocol development worldwide (over 20 countries), monitored status of all studies (nearly 200), monitored and organized regulatory interactions worldwide (e.g., FDA, HPB, HHC, MHC, etc.), and was responsible for all clinical development)As Project Team Leader directed team of multiple disciplines (approximately 25 members, including preclinical and clinical areas, manufacturing regulatory and marketing groups) which was responsible for development of drug. Also directed and coordinated Phase IV and V development, Japan development and regulatory submissions. In this capacity also responsible for coordination of NDA preparation (see below) and monthly presentations to corporate senior management (CEO, COO, etc.).In the NDA project directed, monitored, and coordinated the efforts of more than 200 individuals. NDA delivered on schedule.

Valhalla, Ny, Us

Cardiovascular physiologyLaboratory with Thomas Hintze, Ph.D.

Valhalla, Ny, Us

Valhalla, Ny, Us

Participated in review for all clinical research projects presented to institutional review board. Served as chairman in absence of Chairman of committee. Active in all operational aspects of IRB.

Valhalla, Ny, Us

Valhalla, New York, Us

Valhalla, New York, Us

Valhalla, New York, Us

CardiologyInterventional Cardiology

New York, Ny, Us

Columbus, Oh, Us

Columbus, Oh, Us

Columbus, Oh, Us

Randolph Afb, Tx, Us

Based at Rickenbacker AFB (OH)

Also worked in Psychiatry, Pediatrics, Gynecology

Mba, Strategic Planning, Finance

Public Health (Master In Public Health Program)

Md

Bs, English, Science Pre-Professional

Diploma